Systemic Therapy for Metastatic Non-Clear-Cell Renal Cell Carcinoma: Recent Progress and Future Directions

TY - JOUR

T1 - Systemic Therapy for Metastatic Non-Clear-Cell Renal Cell Carcinoma

T2 - Recent Progress and Future Directions

AU - Chowdhury, Simon

AU - Matrana, Marc R.

AU - Tsang, Christopher

AU - Atkinson, Bradley

AU - Choueiri, Toni K.

AU - Tannir, Nizar M.

PY - 2011/8

Y1 - 2011/8

N2 - Insights into the biology of clear-cell renal cell carcinoma (CCRCC) have identified multiple pathways associated with the pathogenesis and progression of this cancer. This progress has led to the development of multiple agents targeting these pathways, including the tyrosine kinase inhibitors sorafenib, sunitinib, and pazopanib, the monoclonal antibody bevacizumab, and the mTOR inhibitors temsirolimus and everolimus. With the exception of temsirolimus, phase 3 trials tested these agents in patients with clear-cell histology; therefore, their efficacy in non-CCRCC is unclear. To date, there is no established effective therapy for patients with advanced non-CCRCC. This article focuses on treatment options for metastatic non-CCRCC.

AB - Insights into the biology of clear-cell renal cell carcinoma (CCRCC) have identified multiple pathways associated with the pathogenesis and progression of this cancer. This progress has led to the development of multiple agents targeting these pathways, including the tyrosine kinase inhibitors sorafenib, sunitinib, and pazopanib, the monoclonal antibody bevacizumab, and the mTOR inhibitors temsirolimus and everolimus. With the exception of temsirolimus, phase 3 trials tested these agents in patients with clear-cell histology; therefore, their efficacy in non-CCRCC is unclear. To date, there is no established effective therapy for patients with advanced non-CCRCC. This article focuses on treatment options for metastatic non-CCRCC.

KW - Non-clear-cell renal cell carcinoma

KW - Targeted therapy

KW - Papillary

KW - Chromophobe

KW - Unclassified

KW - Renal medullary carcinoma

KW - Collecting duct carcinoma

KW - Sarcomatoid dedifferentiation

KW - ENDOTHELIAL GROWTH-FACTOR

KW - TYROSINE KINASE INHIBITOR

KW - COLLECTING DUCT CARCINOMA

KW - FACTOR-TARGETED THERAPY

KW - OF-THE-LITERATURE

KW - PHASE-II TRIAL

KW - MEDULLARY CARCINOMA

KW - INTERFERON-ALPHA

KW - ANTITUMOR-ACTIVITY

KW - TRANSLOCATION CARCINOMAS

U2 - 10.1016/j.hoc.2011.05.003

DO - 10.1016/j.hoc.2011.05.003

M3 - Article

SN - 0889-8588

VL - 25

SP - 853-+

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 4

ER -